DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: CANCIDAS

Summary for Tradename: CANCIDAS

Patents:5
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 CANCIDAS

Pharmacology for Tradename: CANCIDAS

Ingredient-typeLipopeptides
Drug ClassEchinocandin Antifungal

Clinical Trials for: CANCIDAS

Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Status: Completed Condition: Invasive Fungal Infection

A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
Status: Completed Condition: Fungal Infection

A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074 AM1)
Status: Completed Condition: Fungal Infection

Caspofungin Maximum Tolerated Dose in Patients With Invasive Aspergillosis
Status: Completed Condition: Invasive Aspergillosis

Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
Status: Completed Condition: Candidiasis; Aspergillosis

Open, Pharmacokinetic Study of Caspofungin Acetate in Immunocompromised Young Children With Febrile Neutropenia
Status: Completed Condition: Fungal Infection

Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis
Status: Completed Condition: Fungal Infection

Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067 AM1)
Status: Terminated Condition: Invasive Candidiasis

A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation
Status: Completed Condition: Hematopoietic Stem Cell Transplantation; Fungus Diseases

Optimal Dosage of Caspofungin in Critically Ill Patients
Status: Recruiting Condition: Critically Ill; Suspected Invasive Candidiasis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227Jan 26, 2001RXYes5,378,804*PED<disabled><disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227Jan 26, 2001RXYes5,514,650*PED<disabled>Y<disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227Jan 26, 2001RXYes5,792,746*PED<disabled><disabled>
Merck
CANCIDAS
caspofungin acetate
INJECTABLE;IV (INFUSION)021227Jan 26, 2001RXYes5,952,300*PED<disabled>Y<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: CANCIDAS

Drugname Dosage Strength RLD Submissiondate
caspofungin acetateFor Injection50 mg/vial and 70 mg/vialCancidas6/26/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc